Lab
Bexar County Hospital District
Bexar County Hospital District was paid $91.62M by Medicaid between Jan 2019 and Dec 2024, across 406 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoBEXAR COUNTY HOSPITAL DISTRICT
SAN ANTONIO, TX 78229
SAN ANTONIO, TX 78229
33aNPI1821011248assigned 07/26/2006
33bProvider typeClinical Medical Laboratory
28Total paid$91.62M
24GClaims2,104,292
24DCodes billed406
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#7 of 436
Median peer was paid$17K
This provider vs. median5,311×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 4,288 | $105K | |
| 2020 | 78,329 | $2.06M | |
| 2021 | 511,464 | $20.99M | |
| 2022 | 591,362 | $26.48M | |
| 2023 | 555,607 | $26.28M | |
| 2024incomplete | 363,242 | $15.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 293,566 | 277,947 | $16.29M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 15,370 | 14,105 | $11.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.2% | 8,879 | 8,261 | $7.54M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.9% | 139,828 | 130,584 | $7.26M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 7.8% | 14,331 | 14,015 | $7.12M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 6.9% | 115,680 | 108,869 | $6.37M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 26,561 | 25,690 | $2.28M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.2% | 135,302 | 130,975 | $2.04M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.1% | 42,209 | 39,506 | $1.93M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.0% | 13,265 | 12,433 | $1.85M |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.9% | 132,959 | 65,260 | $1.79M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 7,579 | 7,433 | $1.20M |
394 more codes
| 69210 | 1.1% | 1,531 | $999K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 42,806 | $964K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,415 | $904K |
| 99283 | Emergency room visit (moderate) | <1% | 13,422 | $716K |
| 59025 | Fetal non-stress test | <1% | 4,545 | $673K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,825 | $667K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 23,642 | $648K |
| 76830 | Ultrasound, transvaginal | <1% | 4,736 | $634K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,550 | $630K |
| 81513 | <1% | 5,096 | $598K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,580 | $561K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 862 | $554K |
| G0378 | Hospital observation service, per hour | <1% | 845 | $483K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,569 | $445K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,823 | $443K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,822 | $442K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 9,088 | $432K |
| 80053 | Comprehensive metabolic panel | <1% | 46,656 | $413K |
| 92587 | <1% | 3,009 | $403K | |
| 86850 | <1% | 9,063 | $397K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,356 | $353K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,440 | $333K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 43,071 | $322K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,324 | $316K |
| 76801 | <1% | 2,143 | $300K | |
| 81003 | <1% | 90,945 | $274K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,838 | $273K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,574 | $262K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 374 | $256K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,089 | $243K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,039 | $237K |
| 90474 | <1% | 16,078 | $234K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 103 | $229K |
| 87430 | <1% | 10,785 | $224K | |
| 92567 | <1% | 5,518 | $217K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 491 | $203K |
| 84703 | <1% | 24,813 | $193K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,508 | $192K |
| 90715 | <1% | 10,528 | $175K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,085 | $174K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,281 | $168K |
| 76770 | <1% | 1,207 | $163K | |
| 87070 | <1% | 12,040 | $156K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,223 | $153K |
| 96415 | <1% | 966 | $150K | |
| 87481 | <1% | 5,102 | $145K | |
| 85027 | <1% | 23,737 | $139K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 995 | $137K |
| Q3014 | Telehealth originating site facility fee | <1% | 12,944 | $130K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,286 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,857 | $124K |
| 92579 | <1% | 1,243 | $124K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,625 | $109K |
| 86780 | <1% | 8,131 | $106K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 227 | $105K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,531 | $104K |
| 92557 | <1% | 815 | $104K | |
| 90686 | <1% | 42,698 | $104K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,993 | $102K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,271 | $99K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,607 | $93K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,047 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 728 | $83K |
| 54161 | <1% | 93 | $82K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,134 | $82K |
| 90739 | <1% | 1,090 | $81K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 468 | $81K |
| 81001 | <1% | 24,178 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,920 | $77K |
| 97162 | <1% | 848 | $75K | |
| 64643 | <1% | 331 | $71K | |
| 87340 | <1% | 7,209 | $71K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 914 | $68K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,394 | $67K |
| 94010 | <1% | 718 | $65K | |
| 80061 | Lipid panel | <1% | 10,275 | $63K |
| 90678 | <1% | 205 | $59K | |
| 49083 | <1% | 218 | $58K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 618 | $58K |
| 86762 | <1% | 4,013 | $57K | |
| 88142 | <1% | 2,841 | $57K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,105 | $56K |
| 96367 | <1% | 815 | $56K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 756 | $53K |
| 11721 | <1% | 369 | $48K | |
| 87800 | <1% | 1,159 | $48K | |
| 83735 | <1% | 10,949 | $48K | |
| 64642 | <1% | 230 | $46K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 415 | $46K |
| 90688 | <1% | 12,367 | $46K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,685 | $44K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 110 | $42K |
| 86753 | <1% | 3,433 | $42K | |
| 96417 | <1% | 455 | $41K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,305 | $41K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,888 | $39K |
| 82247 | <1% | 7,205 | $39K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,241 | $39K |
| 20610 | <1% | 234 | $39K | |
| 86900 | <1% | 10,374 | $39K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,415 | $36K |
| 95782 | <1% | 50 | $35K | |
| 87536 | <1% | 817 | $35K | |
| CP007 | <1% | 890 | $35K | |
| 86901 | <1% | 10,371 | $35K | |
| 84702 | <1% | 2,604 | $34K | |
| 96368 | <1% | 468 | $34K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,120 | $34K |
| 90677 | <1% | 722 | $34K | |
| 11982 | <1% | 79 | $33K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 106 | $33K |
| 80197 | <1% | 4,801 | $33K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 508 | $31K |
| 90750 | <1% | 427 | $31K | |
| 84439 | <1% | 3,495 | $30K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,007 | $29K |
| 69209 | <1% | 34 | $29K | |
| 94726 | <1% | 242 | $29K | |
| 86803 | <1% | 3,405 | $29K | |
| 76642 | <1% | 384 | $28K | |
| 93017 | <1% | 159 | $28K | |
| 93975 | <1% | 89 | $27K | |
| 11981 | <1% | 96 | $26K | |
| 95811 | <1% | 40 | $26K | |
| 73630 | <1% | 1,223 | $26K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 510 | $25K |
| 94060 | <1% | 184 | $25K | |
| 83690 | <1% | 4,191 | $25K | |
| 90620 | <1% | 2,453 | $24K | |
| 91320 | <1% | 295 | $24K | |
| 92250 | <1% | 800 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,319 | $23K |
| 87077 | <1% | 3,755 | $22K | |
| 90707 | <1% | 4,047 | $22K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 433 | $22K |
| 84100 | <1% | 7,895 | $21K | |
| 90480 | <1% | 996 | $21K | |
| 82248 | <1% | 3,963 | $21K | |
| 85610 | <1% | 8,334 | $20K | |
| 84484 | <1% | 2,938 | $20K | |
| 73610 | <1% | 786 | $20K | |
| 93970 | <1% | 154 | $19K | |
| 86832 | <1% | 350 | $19K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 358 | $18K |
| 76942 | <1% | 154 | $18K | |
| 73130 | <1% | 737 | $18K | |
| 82977 | <1% | 2,702 | $18K | |
| 86704 | <1% | 1,542 | $18K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 630 | $17K |
| 90656 | <1% | 5,060 | $17K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 42 | $17K |
| 73560 | <1% | 796 | $17K | |
| 86706 | <1% | 1,819 | $17K | |
| 82950 | <1% | 2,476 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 129 | $16K |
| 90716 | <1% | 5,219 | $16K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 927 | $16K |
| 73030 | <1% | 877 | $16K | |
| 90714 | <1% | 1,648 | $16K | |
| 83605 | <1% | 1,911 | $15K | |
| 73562 | <1% | 513 | $15K | |
| 90734 | <1% | 8,190 | $15K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 531 | $15K |
| 77072 | <1% | 363 | $15K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 124 | $15K |
| 90651 | <1% | 8,312 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,443 | $15K |
| 80050 | General health panel | <1% | 292 | $14K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,410 | $14K |
| 82728 | <1% | 1,622 | $14K | |
| 90670 | <1% | 18,436 | $13K | |
| 94618 | <1% | 304 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 616 | $13K |
| 86833 | <1% | 591 | $13K | |
| 95812 | <1% | 25 | $13K | |
| 87186 | <1% | 2,376 | $13K | |
| 99152 | <1% | 911 | $13K | |
| 83520 | <1% | 1,557 | $12K | |
| 87015 | <1% | 1,784 | $12K | |
| 96376 | <1% | 524 | $12K | |
| 85730 | <1% | 3,077 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 273 | $12K |
| 72100 | <1% | 491 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,166 | $11K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 964 | $11K |
| 30930 | <1% | 16 | $11K | |
| 82105 | <1% | 1,149 | $11K | |
| 87081 | <1% | 1,468 | $11K | |
| 73502 | <1% | 434 | $10K | |
| 82570 | <1% | 5,497 | $10K | |
| 87522 | Neg quan hep c or qual rna | <1% | 476 | $10K |
| 93325 | <1% | 63 | $10K | |
| 86140 | <1% | 2,874 | $9K | |
| 87799 | <1% | 1,914 | $9K | |
| 90713 | <1% | 2,941 | $9K | |
| 90671 | <1% | 9,428 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 832 | $8K |
| 76775 | <1% | 207 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,261 | $8K |
| 92582 | <1% | 77 | $8K | |
| 87497 | <1% | 1,316 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 39 | $8K |
| 82803 | <1% | 702 | $8K | |
| 80320 | <1% | 644 | $8K | |
| 80179 | <1% | 631 | $7K | |
| 85384 | <1% | 868 | $7K | |
| 86147 | <1% | 261 | $7K | |
| 76536 | <1% | 92 | $7K | |
| 73110 | <1% | 293 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 217 | $7K |
| 72082 | <1% | 69 | $7K | |
| 85046 | <1% | 1,356 | $7K | |
| 71250 | <1% | 138 | $7K | |
| 86360 | <1% | 404 | $7K | |
| 93971 | <1% | 85 | $6K | |
| 80143 | <1% | 539 | $6K | |
| 83970 | <1% | 589 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,908 | $6K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 83 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 219 | $6K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 12 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 27 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 436 | $5K |
| 77066 | Tomosynthesis, mammo | <1% | 163 | $5K |
| 82550 | <1% | 1,114 | $5K | |
| 94729 | <1% | 202 | $5K | |
| 85055 | <1% | 263 | $5K | |
| 86359 | <1% | 404 | $5K | |
| 97163 | <1% | 53 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 698 | $5K |
| 82607 | <1% | 800 | $5K | |
| 86480 | <1% | 170 | $5K | |
| 95851 | <1% | 431 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 35 | $5K |
| 73590 | <1% | 257 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 565 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 47 | $5K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 452 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 161 | $5K |
| 83550 | <1% | 1,112 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,375 | $4K |
| 81379 | <1% | 16 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 741 | $4K |
| 82043 | <1% | 2,269 | $4K | |
| 81382 | <1% | 23 | $4K | |
| 82951 | <1% | 304 | $4K | |
| 36592 | <1% | 146 | $4K | |
| 87102 | <1% | 501 | $4K | |
| 85652 | <1% | 2,198 | $4K | |
| 90732 | <1% | 240 | $4K | |
| 86038 | <1% | 397 | $3K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 25 | $3K |
| 80069 | <1% | 1,026 | $3K | |
| J0586 | Injection, abobotulinumtoxina, 5 units | <1% | 19 | $3K |
| 83540 | <1% | 1,137 | $3K | |
| 74018 | <1% | 82 | $3K | |
| 88342 | <1% | 134 | $3K | |
| 97161 | <1% | 55 | $3K | |
| 93320 | <1% | 13 | $3K | |
| 30802 | <1% | 12 | $3K | |
| 31575 | <1% | 39 | $3K | |
| 92083 | <1% | 30 | $3K | |
| 84156 | <1% | 2,812 | $3K | |
| 87040 | <1% | 382 | $3K | |
| 90746 | <1% | 125 | $3K | |
| 87206 | <1% | 608 | $3K | |
| 82150 | <1% | 528 | $3K | |
| 83020 | <1% | 204 | $3K | |
| 72170 | <1% | 66 | $3K | |
| 81025 | <1% | 383 | $3K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 170 | $2K |
| 36591 | <1% | 40 | $2K | |
| 82565 | <1% | 1,002 | $2K | |
| 82746 | <1% | 331 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 44 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 282 | $2K |
| 86849 | <1% | 377 | $2K | |
| 96381 | <1% | 177 | $2K | |
| 73552 | <1% | 97 | $2K | |
| 70486 | <1% | 26 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,809 | $2K |
| 86682 | <1% | 102 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 629 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 624 | $2K |
| 73521 | <1% | 29 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,969 | $2K |
| 80074 | <1% | 186 | $2K | |
| 98960 | <1% | 373 | $1K | |
| 83516 | <1% | 220 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 324 | $1K |
| 87653 | <1% | 46 | $1K | |
| 82140 | <1% | 156 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 840 | $1K |
| 82952 | <1% | 288 | $1K | |
| 36410 | <1% | 72 | $1K | |
| 82947 | <1% | 156 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 572 | $980.71 |
| 80076 | <1% | 267 | $953.34 | |
| 87205 | <1% | 469 | $940.95 | |
| 92504 | <1% | 28 | $932.18 | |
| 83655 | <1% | 65 | $929.81 | |
| 93990 | <1% | 28 | $863.10 | |
| 72081 | <1% | 16 | $848.53 | |
| 73070 | <1% | 43 | $812.43 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 37 | $811.32 |
| 86160 | <1% | 53 | $806.83 | |
| 90658 | <1% | 38 | $805.27 | |
| 84550 | <1% | 907 | $748.73 | |
| 86787 | <1% | 43 | $747.56 | |
| 90381 | <1% | 78 | $713.63 | |
| 77080 | <1% | 93 | $686.71 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 49 | $677.00 |
| 92015 | Determination of refractive state | <1% | 88 | $648.15 |
| 86200 | <1% | 37 | $615.06 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 90 | $606.19 |
| 93922 | <1% | 12 | $580.63 | |
| 74019 | <1% | 12 | $577.06 | |
| 84460 | <1% | 76 | $559.87 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 77 | $519.11 |
| 72110 | <1% | 12 | $489.81 | |
| 90680 | <1% | 16,554 | $474.91 | |
| 96523 | <1% | 17 | $456.41 | |
| 72040 | <1% | 14 | $446.62 | |
| 88313 | <1% | 26 | $423.04 | |
| 84450 | <1% | 80 | $418.78 | |
| 85014 | <1% | 625 | $415.16 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 55 | $413.48 |
| 88341 | <1% | 24 | $412.62 | |
| 95012 | <1% | 16 | $410.41 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 70 | $366.90 |
| 86225 | <1% | 15 | $354.88 | |
| 82330 | <1% | 137 | $347.99 | |
| 85018 | <1% | 397 | $345.26 | |
| 86580 | <1% | 44 | $340.30 | |
| 90673 | <1% | 147 | $336.83 | |
| 84305 | <1% | 13 | $316.09 | |
| 90710 | <1% | 2,867 | $312.49 | |
| 86923 | <1% | 21 | $306.90 | |
| 90648 | <1% | 26,753 | $305.51 | |
| 90723 | <1% | 19,621 | $296.81 | |
| 80321 | <1% | 13 | $295.76 | |
| 82784 | <1% | 69 | $290.41 | |
| 88307 | <1% | 16 | $281.66 | |
| 87147 | <1% | 72 | $257.40 | |
| 82962 | <1% | 3,465 | $254.35 | |
| 73090 | <1% | 13 | $252.12 | |
| 90473 | <1% | 12 | $247.50 | |
| 90696 | <1% | 2,600 | $244.15 | |
| 90633 | <1% | 13,434 | $188.70 | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 297 | $174.85 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 347 | $127.99 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 64 | $124.14 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,092 | $114.91 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,735 | $102.14 |
| 85660 | <1% | 50 | $99.56 | |
| 87338 | <1% | 12 | $88.23 | |
| 87073 | <1% | 14 | $71.59 | |
| 90744 | <1% | 2,687 | $70.64 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 168 | $66.70 |
| 80051 | <1% | 27 | $60.52 | |
| 87517 | <1% | 13 | $51.65 | |
| 90662 | <1% | 33 | $47.86 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 14 | $43.05 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 25 | $41.29 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 16 | $37.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 44 | $33.27 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 26 | $32.86 |
| 86708 | <1% | 12 | $31.23 | |
| 90700 | <1% | 4,056 | $22.57 | |
| 84132 | <1% | 24 | $17.74 | |
| C1769 | Guide wire | <1% | 343 | $11.70 |
| G0008 | Administration of influenza virus vaccine | <1% | 1,965 | $1.71 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,584 | $0.04 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 40 | $0.00 |
| 90685 | 0% | 197 | $0.00 | |
| 90380 | 0% | 25 | $0.00 | |
| 90611 | 0% | 18 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 66 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 28 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 18 | $0.00 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 30 | $0.00 |
| 90655 | 0% | 13 | $0.00 | |
| 36416 | 0% | 916 | $0.00 | |
| 90378 | 0% | 117 | $0.00 | |
| 90698 | 0% | 558 | $0.00 | |
| 91318 | 0% | 298 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 295 | $0.00 |
| 91319 | 0% | 104 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 174 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 12 | $0.00 |
| 88300 | 0% | 15 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 47 | $0.00 |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHURLEY, REED (EXECUTIVE VICE PRESIDENT CFO)
| Provider | Location | Paid |
|---|---|---|
| Bexar County Hospital District | San Antonio, TX | $198K |
| Bexar County Hospital District | San Antonio, TX | $35K |
| Bexar County Hospital District | San Antonio, TX | $19K |
| Bexar County Hospital District | San Antonio, TX | $12K |
| Bexar County Hospital District | San Antonio, TX | $832.57 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.